Personalized medicine最新文献

筛选
英文 中文
Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer. DPYD、MTHFR和TYMS多态性对结直肠癌5-氟尿嘧啶相关毒性的影响
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-26 DOI: 10.2217/pme-2021-0047
Mehtap Cevik, Esat Namal, Nur Dinc Sener, Ulkuhan Iner Koksal, Penbe Cagatay, Gokce Deliorman, Cavlan Ciftci, Atila Karaalp, Belgin Susleyici
{"title":"Investigation of <i>DPYD</i>, <i>MTHFR</i> and <i>TYMS</i> polymorphisms on 5-fluorouracil related toxicities in colorectal cancer.","authors":"Mehtap Cevik,&nbsp;Esat Namal,&nbsp;Nur Dinc Sener,&nbsp;Ulkuhan Iner Koksal,&nbsp;Penbe Cagatay,&nbsp;Gokce Deliorman,&nbsp;Cavlan Ciftci,&nbsp;Atila Karaalp,&nbsp;Belgin Susleyici","doi":"10.2217/pme-2021-0047","DOIUrl":"https://doi.org/10.2217/pme-2021-0047","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the association of <i>DPYD</i>, <i>MTHFR</i> and <i>TYMS</i> polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. <b>Materials & methods:</b> A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several <i>DPYD</i>, <i>MTHFR</i> and <i>TYMS</i> polymorphisms using a microarray analyzer. <b>Results:</b> <i>DPYD</i> 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0-2, but not severe toxicities (p = 0.02). Furthermore, patients with <i>DPYD</i> 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60; p = 0.01 and log rank = 4.40; p = 0.04, respectively). <b>Conclusion:</b> According to our results, <i>DPYD</i> 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another <i>DPYD</i> polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"435-444"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40554983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. 基于rna的下一代测序在非小细胞肺癌的常规设置:来自意大利转诊中心的经验。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-08 DOI: 10.2217/pme-2022-0020
Caterina De Luca, Francesco Pepe, Pasquale Pisapia, Antonino Iaccarino, Luisella Righi, Angela Listì, Gianluca Russo, Severo Campione, Fabio Pagni, Mariantonia Nacchio, Floriana Conticelli, Maria Russo, Teresa Fabozzi, Elena Vigliar, Claudio Bellevicine, Danilo Rocco, Stefano Laudati, Giuseppe Iannaci, Bruno Daniele, Cesare Gridelli, Diego Luigi Cortinovis, Silvia Novello, Miguel Angel Molina-Vila, Rafael Rosell, Giancarlo Troncone, Umberto Malapelle
{"title":"RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.","authors":"Caterina De Luca,&nbsp;Francesco Pepe,&nbsp;Pasquale Pisapia,&nbsp;Antonino Iaccarino,&nbsp;Luisella Righi,&nbsp;Angela Listì,&nbsp;Gianluca Russo,&nbsp;Severo Campione,&nbsp;Fabio Pagni,&nbsp;Mariantonia Nacchio,&nbsp;Floriana Conticelli,&nbsp;Maria Russo,&nbsp;Teresa Fabozzi,&nbsp;Elena Vigliar,&nbsp;Claudio Bellevicine,&nbsp;Danilo Rocco,&nbsp;Stefano Laudati,&nbsp;Giuseppe Iannaci,&nbsp;Bruno Daniele,&nbsp;Cesare Gridelli,&nbsp;Diego Luigi Cortinovis,&nbsp;Silvia Novello,&nbsp;Miguel Angel Molina-Vila,&nbsp;Rafael Rosell,&nbsp;Giancarlo Troncone,&nbsp;Umberto Malapelle","doi":"10.2217/pme-2022-0020","DOIUrl":"https://doi.org/10.2217/pme-2022-0020","url":null,"abstract":"<p><p><b>Aim:</b> <i>ALK</i>, <i>ROS1</i>, <i>NTRK</i> and <i>RET</i> gene fusions and <i>MET</i> exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next-generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants. <b>Materials & methods:</b> In the present study, we report our NGS molecular records produced during a year of diagnostic activity. <b>Results:</b> Overall, our in-house developed NGS workflow successfully analyzed n = 116/131 (88.5%) NSCLC samples. Of these, eight (6.8%) and five (4.3%) out of 116 patients harbored <i>ALK</i> and <i>RET</i> gene rearrangements, respectively: one case harbored <i>ROS1</i> gene fusion (0.7%). <b>Conclusion:</b> Our results highlight that an RNA-based NGS analysis can reliably detect gene fusion alterations, thereby playing a pivotal role in the management of NSCLC patients.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"395-401"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40594802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients. 突尼斯肾移植患者霉酚酸酯的药物遗传学研究。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-06-30 DOI: 10.2217/pme-2021-0092
Amani Abderahmene, Amel Ellouz, Dorra Amor, Marwa Ajmi, Yassine Khalij, Haithem Hamdouni, Wissal Sahtout, Awatef Azzabi, Asma Omezzine, Abdellatif Achour, Ali Bouslama
{"title":"The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients.","authors":"Amani Abderahmene,&nbsp;Amel Ellouz,&nbsp;Dorra Amor,&nbsp;Marwa Ajmi,&nbsp;Yassine Khalij,&nbsp;Haithem Hamdouni,&nbsp;Wissal Sahtout,&nbsp;Awatef Azzabi,&nbsp;Asma Omezzine,&nbsp;Abdellatif Achour,&nbsp;Ali Bouslama","doi":"10.2217/pme-2021-0092","DOIUrl":"https://doi.org/10.2217/pme-2021-0092","url":null,"abstract":"<p><p><b>Aim:</b> The effects of variants in <i>IMPDH, UGT1A9, UGT1A8, UGT2B7</i> and <i>SLCO1B1</i> genes on the efficacy and safety of mycophenolate mofetil (MMF) in the Tunisian population were investigated. <b>Materials & methods:</b> A total of 245 kidney transplant patients being treated with MMF were recruited and cotreated with cyclosporine or tacrolimus. Genotyping was performed using the polymerase chain reaction-restriction fragment length polymorphism method. MMF, cyclosporine and tacrolimus trough levels were measured by immunoassay. The AUC (AUC<sub>0-12h</sub>MPA) was estimated by a Bayesian method. <b>Results:</b> In the tacrolimus-treated group, anemia and diarrhea were associated with the <i>UGT1A9-98C</i> and <i>UGT1A9-275T</i> alleles, respectively (p < 0.05). In the cyclosporine-treated group, leukopenia was associated with the SLCO1B1-521T allele (p < 0.05). Both groups had an increased risk of rejection (p < 0.05) associated with the variant alleles of <i>IMPDH2-3757T>C</i>, <i>UGT1A9-2152C>T</i> and <i>UGT1A9-275C>A</i> and the common allele of <i>SLCO1B1-388A>G</i>. However, no significant association was found between the studied genotypes and AUC<sub>0-12h</sub>MPA or cotreatment levels. <b>Conclusion:</b> The results constitute preliminary evidence for the inclusion of the pharmacogenetics of MMF in kidney pretransplantation evaluations.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"383-393"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40411049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetic testing in pediatric neurology: a pragmatic study evaluating clinician and patient perceptions. 儿童神经病学的药物遗传学测试:一项评估临床医生和患者认知的实用研究。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-13 DOI: 10.2217/pme-2021-0150
Marie-Anne Pépin, Anne-Sophie Otis, Zoë Tremblay, Marianne Boulé, Denis Lebel, Philippe Major, Anne Lortie, Elana Pinchefsky, Elsa Rossignol, Bruce Carleton, Jean-François Bussières, Marie-Élaine Métras
{"title":"Pharmacogenetic testing in pediatric neurology: a pragmatic study evaluating clinician and patient perceptions.","authors":"Marie-Anne Pépin,&nbsp;Anne-Sophie Otis,&nbsp;Zoë Tremblay,&nbsp;Marianne Boulé,&nbsp;Denis Lebel,&nbsp;Philippe Major,&nbsp;Anne Lortie,&nbsp;Elana Pinchefsky,&nbsp;Elsa Rossignol,&nbsp;Bruce Carleton,&nbsp;Jean-François Bussières,&nbsp;Marie-Élaine Métras","doi":"10.2217/pme-2021-0150","DOIUrl":"https://doi.org/10.2217/pme-2021-0150","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate clinicians' and patients' perceptions of pharmacogenetic testing in a clinical setting. <b>Materials & methods:</b> This is a pragmatic mixed-method prospective observational study. Hospital pharmacists and neurologists participated in focus groups regarding pharmacogenetic testing; patients who received pharmacogenetic testing and their community pharmacists completed surveys to assess their perception of these tests. <b>Results:</b> Most study participants had a positive view of pharmacogenetic testing. Three major themes were identified from the focus groups: receptiveness to pharmacogenetic testing, pharmacogenetic test characteristics and integrating pharmacogenetic tests into practice. <b>Conclusion:</b> The views reported are encouraging for the eventual implementation of pharmacogenetics in practice. Local integration of these tests is an essential step to improve patient care through personalized medicine.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"423-434"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40501674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in healthcare: a primer for medical education in radiomics. 医疗保健中的人工智能:放射组学医学教育入门。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-26 DOI: 10.2217/pme-2022-0014
Carly E Waldman, Melody Hermel, Jonathan A Hermel, Francis Allinson, Mark N Pintea, Natalie Bransky, Emem Udoh, Laura Nicholson, Austin Robinson, Jorge Gonzalez, Christopher Suhar, Keshav Nayak, George Wesbey, Sanjeev P Bhavnani
{"title":"Artificial intelligence in healthcare: a primer for medical education in radiomics.","authors":"Carly E Waldman,&nbsp;Melody Hermel,&nbsp;Jonathan A Hermel,&nbsp;Francis Allinson,&nbsp;Mark N Pintea,&nbsp;Natalie Bransky,&nbsp;Emem Udoh,&nbsp;Laura Nicholson,&nbsp;Austin Robinson,&nbsp;Jorge Gonzalez,&nbsp;Christopher Suhar,&nbsp;Keshav Nayak,&nbsp;George Wesbey,&nbsp;Sanjeev P Bhavnani","doi":"10.2217/pme-2022-0014","DOIUrl":"https://doi.org/10.2217/pme-2022-0014","url":null,"abstract":"<p><p>The application of artificial intelligence (AI) to healthcare has garnered significant enthusiasm in recent years. Despite the adoption of new analytic approaches, medical education on AI is lacking. We aim to create a usable AI primer for medical education. We discuss how to generate a clinical question involving AI, what data are suitable for AI research, how to prepare a dataset for training and how to determine if the output has clinical utility. To illustrate this process, we focused on an example of how medical imaging is employed in designing a machine learning model. Our proposed medical education curriculum addresses AI's potential and limitations for enhancing clinicians' skills in research, applied statistics and care delivery.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"445-456"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40539578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population. 中国白族人群CYP3A5、ACE、PTGS2和NAT2基因的药物基因组学分析。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-08 DOI: 10.2217/pme-2021-0157
Wenting Meng, Wenjie Zhang, Shuangyu Yang, Xia Dou, Yuanwei Liu, Haiyue Li, Jianfeng Liu, Tianbo Jin, Bin Li
{"title":"Analysis of pharmacogenomic very important pharmacogenomic variants: <i>CYP3A5</i>, <i>ACE</i>, <i>PTGS2</i> and <i>NAT2</i> genes in Chinese Bai population.","authors":"Wenting Meng,&nbsp;Wenjie Zhang,&nbsp;Shuangyu Yang,&nbsp;Xia Dou,&nbsp;Yuanwei Liu,&nbsp;Haiyue Li,&nbsp;Jianfeng Liu,&nbsp;Tianbo Jin,&nbsp;Bin Li","doi":"10.2217/pme-2021-0157","DOIUrl":"https://doi.org/10.2217/pme-2021-0157","url":null,"abstract":"<p><p><b>Aim:</b> Our study aimed to screen the genotype frequencies of very important pharmacogenomic (VIP) mutations and identify their differences between Bai and other populations. <b>Materials & methods:</b> We selected 66 VIP variants from PharmGKB (www.pharmgkb.org/) for genotyping. χ2 test was used to identify differences in <i>loci</i> between these populations and FST values of Bai and the other 26 populations were analyzed. <b>Results:</b> Our study showed that the frequencies of SNPs of <i>CYP3A5</i>, <i>ACE</i>, <i>PTGS2</i> and <i>NAT2</i> differed significantly from those of the other 26 populations. At the same time, we found that some VIP variants may affect the metabolism of drugs and the genetic relationship between the Bai population and East Asian populations was found to be the closest. <b>Conclusion:</b> By comparing the genotype frequencies of different populations, the <i>loci</i> with significant differences were identified and discussed, providing a theoretical basis for individualized drug use in the Bai ethnic population.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"403-410"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40570607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A sociogenomic paradigm to replace the racial paradigm. 用社会基因组学范式来取代种族范式。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-06-27 DOI: 10.2217/pme-2021-0141
Sajith Matthews, Phillip D Levy
{"title":"A sociogenomic paradigm to replace the racial paradigm.","authors":"Sajith Matthews,&nbsp;Phillip D Levy","doi":"10.2217/pme-2021-0141","DOIUrl":"https://doi.org/10.2217/pme-2021-0141","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"377-382"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40403488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. 亚裔、夏威夷原住民和太平洋岛民亚群妇女中主要 CYP2C19 基因多态性的频率。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-07-01 Epub Date: 2022-06-24 DOI: 10.2217/pme-2021-0175
Khalifa Y Alrajeh, Youssef M Roman
{"title":"The frequency of major <i>CYP2C19</i> genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.","authors":"Khalifa Y Alrajeh, Youssef M Roman","doi":"10.2217/pme-2021-0175","DOIUrl":"10.2217/pme-2021-0175","url":null,"abstract":"<p><p><b>Aim:</b> Prevalence of clinically actionable genetic variants of <i>CYP2C19</i> is lacking in specific population subgroups. This study aims to assess the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in Asian, Native Hawaiian and Pacific Islander (NHPI) population subgroups compared with Europeans. <b>Patients & methods:</b> The study included repository DNA samples of 1064 women, 18 years or older, who self-reported as Filipino, Korean, Japanese, Native Hawaiian, Marshallese and Samoan. <b>Results:</b> The overall frequencies of <i>CYP2C19*2</i> (25-36%) and <i>CYP2C19*3</i> (2.5-10%) were significantly higher in all our subgroups than in Europeans (15 and 0.02%, respectively). The overall frequency of <i>CYP2C19*17</i> was significantly lower in all our subgroups (1-6%) than in Europeans (21.7%). <b>Conclusion:</b> This is the first report on the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in women of Asian and NHPI descent with distinct population subgroup differences. Differential allele frequencies of <i>CYP2C19</i> among population subgroups underscore the importance of increasing racial and ethnic diversity in pharmacogenetic research.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 4","pages":"327-339"},"PeriodicalIF":2.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318053/pdf/pme-19-327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the quality of the economic evidence in colorectal cancer genomics studies. 评估结直肠癌基因组学研究中经济证据的质量。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-07-01 Epub Date: 2022-07-05 DOI: 10.2217/pme-2021-0006
Vivek S Chaudhari, Kanchan C Hole, Amalia M Issa
{"title":"Evaluating the quality of the economic evidence in colorectal cancer genomics studies.","authors":"Vivek S Chaudhari,&nbsp;Kanchan C Hole,&nbsp;Amalia M Issa","doi":"10.2217/pme-2021-0006","DOIUrl":"https://doi.org/10.2217/pme-2021-0006","url":null,"abstract":"<p><p>The increase in the use of genome-based screening and diagnostic tests adds to the overall costs of oncologic care for colorectal cancer. This, in turn, has resulted in an increase in published economic analyses. <b>Aim:</b> To perform a systematic literature review of the available economic evidence evaluating the value of genomic testing for colorectal cancer and appraise the quality of the economic studies conducted to date. <b>Methods:</b> A systematic review of the literature for economic studies of colorectal cancer genomics from January 2006 through October 2020, and evaluation of study quality using the Quality of Health Economic Studies (QHES) instrument was conducted. The validated QHES was then applied to a final set of articles that met eligibility criteria. <b>Results:</b> Our search of the literature initially yielded 12,859 records. A final set of 49 articles met our inclusion criteria. The QHES score ranged from 24 to 100, with an average score of 82. Most of the studies (n = 40, 82%) scored above 75 and were considered of good quality. <b>Conclusion:</b> Our analysis revealed that most of the economic analyses of colorectal cancer genomic molecular diagnostics in the literature may be of good quality. There is, however, some variation in methodological rigor between the articles.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"361-375"},"PeriodicalIF":2.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40480000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting molecular alterations in non-small-cell lung cancer: what's next? 靶向非小细胞肺癌的分子改变:下一步是什么?
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-07-01 Epub Date: 2022-06-24 DOI: 10.2217/pme-2021-0059
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita
{"title":"Targeting molecular alterations in non-small-cell lung cancer: what's next?","authors":"Rafael López-Castro,&nbsp;Tania García-Peña,&nbsp;Xabier Mielgo-Rubio,&nbsp;Mariona Riudavets,&nbsp;Cristina Teixidó,&nbsp;Noelia Vilariño,&nbsp;Felipe Couñago,&nbsp;Laura Mezquita","doi":"10.2217/pme-2021-0059","DOIUrl":"https://doi.org/10.2217/pme-2021-0059","url":null,"abstract":"<p><p>In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art management of patients with NSCLC (particularly adenocarcinoma or non-adenocarcinoma but with mild tobacco exposure) consists of the determination of <i>EGFR</i>, <i>ALK</i>, <i>ROS1</i> and <i>BRAF</i> status, as they have US FDA and EMA approved targeted therapies. The increase in molecular knowledge of NSCLC and the development of drugs against other targets has settled new therapeutic indications. In this review we have incorporated the development around MET, KRAS and NTRK in the diagnosis of NSCLC given the therapeutic potential that they represent, as well as the drugs approved for these indications.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"341-359"},"PeriodicalIF":2.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信